If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||
![]() CephalalgiaVolume 22 Issue 9, Pages 740 - 748 Published Online: 6 Nov 2002 © 2009 International Headache Society Published on behalf of the International Headache Society
Abstract | References | Full Text: HTML, PDF (Size: 97K) | Related Articles | Citation Tracking Efficacy and safety of acetaminophen and naproxen in the treatment of tension-type headache. A randomized, double-blind, placebo-controlled trial Copyright Blackwell Science, 2002 KEYWORDS Acetaminophen • naproxen • tension-type headache • analgesic Prior MJ, Cooper KM, May LG & Bowen DL. Efficacy and safety of acetaminophen and naproxen in the treatment of tension-type headache. A randomized, double-blind, placebo-controlled trial. Cephalalgia 2002; 22:740–748. London. ISSN 0333-1024 ABSTRACTThe objective of this study was to evaluate and compare the efficacy and safety of single doses of acetaminophen (paracetamol) 1000 mg and naproxen 375 mg vs. placebo over a six-hour period in the treatment of tension-type headache. The treatments were compared in a randomized, double-blind, multicentre, placebo-controlled study. Efficacy was evaluated using four standard analgesic summary endpoints (the sum of pain intensity differences from baseline, the maximum pain intensity from baseline, the sum of the pain relief scores, and the maximum pain relief score). Both acetaminophen 1000 mg and naproxen 375 mg were significantly superior to placebo (P≤0.009 and P≤0.021, respectively) but not significantly different from each other (P≥0.498) for these four endpoints. For example, the mean sum of pain intensity differences from baseline was 9.14±0.34 for acetaminophen 1000 mg and 8.81±0.35 for naproxen 375 mg compared with 7.42±0.34 for placebo. Other efficacy endpoints (percentage of responders (pain reduced to none) at two hours, onset of meaningful relief, time to use of rescue medication and subject's overall impression of study medication) showed similar trends. A significantly larger mean pain intensity difference from baseline was observed for acetaminophen 1000 mg (1.13) than for naproxen 375 mg (0.95) (P=0.036) at one hour after treatment. There was no significant difference among the treatment groups in the incidence of adverse events (P=0.730). In summary, the results of this well-controlled, double-blind study demonstrate that over-the-counter acetaminophen 1000 mg and prescription naproxen 375 mg are effective and well tolerated in the treatment of tough (moderate-to-severe) tension-type headache. Received 20 November 2001, accepted 31 May 2002 |